nach oben

Erschienen in:

14.01.2019 | Chest

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer

verfasst von: Linlin Wang, Taotao Dong, Bowen Xin, Chongrui Xu, Meiying Guo, Huaqi Zhang, Dagan Feng, Xiuying Wang, Jinming Yu

Erschienen in: European Radiology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine the integrative value of clinical, hematological, and computed tomography (CT) radiomic features in survival prediction for locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Methods

Radiomic features and clinical and hematological features of 118 LA-NSCLC cases were firstly extracted and analyzed in this study. Then, stable and prognostic radiomic features were automatically selected using the consensus clustering method with either Cox proportional hazard (CPH) model or random survival forest (RSF) analysis. Predictive radiomic, clinical, and hematological parameters were subsequently fitted into a final prognostic model using both the CPH model and the RSF model. A multimodality nomogram was then established from the fitting model and was cross-validated. Finally, calibration curves were generated with the predicted versus actual survival status.

Results

Radiomic features selected by clustering combined with CPH were found to be more predictive, with a C-index of 0.699 in comparison to 0.648 by clustering combined with RSF. Based on multivariate CPH model, our integrative nomogram achieved a C-index of 0.792 and retained 0.743 in the cross-validation analysis, outperforming radiomic, clinical, or hematological model alone. The calibration curve showed agreement between predicted and actual values for the 1-year and 2-year survival prediction. Interestingly, the selected important radiomic features were significantly correlated with levels of platelet, platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) (p values all < 0.05).

Conclusions

The integrative nomogram incorporated CT radiomic, clinical, and hematological features improved survival prediction in LA-NSCLC patients, which would offer a feasible and practical reference for individualized management of these patients.

Key Points

• An integrative nomogram incorporated CT radiomic, clinical, and hematological features was constructed and cross-validated to predict prognosis of LA-NSCLC patients.

• The integrative nomogram outperformed radiomic, clinical, or hematological model alone.

• This nomogram has value to permit non-invasive, comprehensive, and dynamical evaluation of the phenotypes of LA-NSCLC and can provide a feasible and practical reference for individualized management of LA-NSCLC patients.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global Cancer Statistics. CA Cancer J Clin 61:69–90

Yang P, Allen MS, Aubry MC et al (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128:452–462CrossRefPubMed

Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190CrossRefPubMed

Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non–small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760CrossRefPubMed

Vokes EE, Herndon JE 2nd, Kelley MJ et al (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non–small-cell lung cancer: cancer and leukemia group B. J Clin Oncol 25:1698

Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRefPubMed

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577CrossRefPubMed

Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749CrossRefPubMed

Agrawal V, Coroller TP, Ying H et al (2016) Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. Lung Cancer 102:1CrossRefPubMed

10.

Hatt M, Majdoub M, Vallières M et al (2015) 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 56:38–44

11.

Kirienko M, Gallivanone F, Sollini M et al (2017) FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer. Front Biosci (Landmark Ed) 22:1713CrossRef

12.

Desseroit MC, Visvikis D, Tixier F et al (2016) Erratum to: development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III. Eur J Nucl Med Mol Imaging 43:1477–1485CrossRefPubMedPubMedCentral

13.

Pyka T, Bundschuh RA, Andratschke N et al (2015) Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol 10:100CrossRefPubMedPubMedCentral

14.

Schernberg A, Reuze S, Orlhac F et al (2018) A score combining baseline neutrophilia and primary tumor SUV_peak measured from FDG PET is associated with outcome in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging 45:187–195CrossRefPubMed

15.

Scilla KA, Bentzen SM, Lam VK et al (2017) Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 22:737–742CrossRefPubMedPubMedCentral

16.

Bremnes RM, Al-Shibli K, Donnem T et al (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833CrossRefPubMed

17.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570CrossRefPubMed

18.

Oberije C, De Ruysscher D, Houben R et al (2015) A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 92:935CrossRefPubMedPubMedCentral

19.

Tanadini-Lang S, Rieber J, Filippi AR et al (2017) Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol 123:182–188

20.

Tang XR, Li YQ, Liang SB et al (2018) Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol 19:382–393

21.

Cui H, Wang X, Zhou J et al (2015) Topology polymorphism graph for lung tumor segmentation in PET-CT images. Phys Med Biol 60:4893–4914CrossRefPubMed

22.

Cui H, Wang X, Zhou J et al (2018) A topo-graph model for indistinct target boundary definition from anatomical images. Comput Methods Programs Biomed 159:211–222

23.

Leger S, Zwanenburg A, Pilz K et al (2017) A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Sci Rep 7:13206CrossRefPubMedPubMedCentral

24.

Gerds TA, Kattan MW, Schumacher M, Yu C (2013) Estimating a time-dependent concordance index for survival prediction models with covariate dependent censoring. Stat Med 32:2173–2184CrossRefPubMed

25.

Grossmann P, Stringfield O, El-Hachem N et al (2017) Defining the biological basis of radiomic phenotypes in lung cancer. Elife 6:e23421

26.

Fave X, Zhang L, Yang J et al (2017) Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer. Sci Rep 7:588CrossRefPubMedPubMedCentral

27.

Lee J, Li B, Cui Y et al (2018) A quantitative CT imaging signature predicts survival and complements established prognosticators in stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 102:1098–1106

28.

Huang Y, Liu Z, He L et al (2016) Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer. Radiology 281:947CrossRefPubMed

29.

Ohri N, Duan F, Snyder BS et al (2016) Pretreatment 18FDG-PET textural features in locally advanced non-small cell lung cancer: secondary analysis of ACRIN 6668/RTOG 0235. J Nucl Med 57:228–233CrossRef

30.

Salavati A, Duan F, Snyder BS et al (2017) Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 44:1969–1983CrossRefPubMedPubMedCentral

31.

Rao SX, Lambregts DM, Schnerr RS et al (2016) CT texture analysis in colorectal liver metastases: a better way than size and volume measurements to assess response to chemotherapy? United European Gastroenterol J 4:257–263CrossRefPubMed

32.

Dong X, Sun X, Sun L et al (2016) Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer. PLoS One 11:e0157836CrossRefPubMedPubMedCentral

33.

Cunliffe A, Armato SG 3rd, Castillo R, Pham N, Guerrero T, Al-Hallaq HA (2015) Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys 91:1048–1056

34.

Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ (2000) Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 29:169–177CrossRefPubMed

35.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545CrossRefPubMed

36.

Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A (2013) Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 228:1404–1412CrossRefPubMed

37.

Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91:411–429CrossRef

38.

Liu HB, Gu XL, Ma XQ et al (2013) Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. Neoplasma 60:203–208CrossRefPubMed

39.

Li Y, Jia H, Yu W et al (2016) Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection. Int J Cancer 139:220–231CrossRefPubMed

40.

Cannon NA, Meyer J, Iyengar P et al (2015) Neutrophil–lymphocyte and platelet–lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non–small-cell lung cancer. J Thorac Oncol 10:280–285CrossRefPubMed

41.

Gittleman H, Lim D, Kattan MW et al (2017) An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol 19:669–677CrossRefPubMed

Titel: Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer
verfasst von: Linlin Wang
Taotao Dong
Bowen Xin
Chongrui Xu
Meiying Guo
Huaqi Zhang
Dagan Feng
Xiuying Wang
Jinming Yu
Publikationsdatum: 14.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 6/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5949-2

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer